Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats

International Immunopharmacology
W Brooks GentryS Michael Owens

Abstract

The purpose of these studies was to determine if a high-affinity, anti-(+)-methamphetamine (METH) monoclonal antibody (mAb6H4; KD=11 nM) protects against METH-induced central nervous and cardiovascular system effects in rats. Rats (n=5 per group) received one of three anti-METH mAb6H4 doses, equal to 0.32, 0.56 or 1 times the mole equivalent (mol-eq) amount of METH in the body following a 1 mg/kg i.v. METH dose. Each rat was challenged with METH (1 mg/kg, i.v.) 1 and 4 days after the anti-METH mAb dose. The 1 mol-eq anti-METH mAb dose significantly reduced the duration of METH-induced locomotor activity (horizontal locomotion and rearing events), heart rate and blood pressure effects from 2 to 3 h to about an hour. This resulted in a significant reduction in total locomotor activity and the area under the hemodynamic effect vs. time curve for heart rate and blood pressure. In addition, the time to peak locomotor activity was decreased after the 1 mol-eq mAb dose vs. the lower doses. These changes were limited to the first METH challenge. The responses to the second METH challenge were not different from baseline. The peak hemodynamic and locomotor activity values were unchanged after both challenges. These results indicate anti...Continue Reading

References

Jan 1, 1991·Clinical and Experimental Hypertension. Part A, Theory and Practice·B P BrockwayS H Azar
Mar 1, 1997·The Journal of Pharmacy and Pharmacology·M I Bazin-RedureauJ M Scherrmann
Aug 30, 2001·European Journal of Pharmacology·H AroraW B Gentry
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·J Shane HardinS Michael Owens
Jun 28, 2003·The Journal of Pharmacology and Experimental Therapeutics·Elizabeth M LaurenzanaS Michael Owens
Oct 23, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Elizabeth M LaurenzanaS Michael Owens
Jan 24, 2004·Bioorganic & Medicinal Chemistry·M Rocío A CarreraKim D Janda
Mar 3, 2004·The Journal of Pharmacology and Experimental Therapeutics·D E McMillanS M Owens
Jun 3, 2004·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·H P HendricksonS M Owens

❮ Previous
Next ❯

Citations

Oct 5, 2007·Current Psychiatry Reports·Frank M OrsonThomas R Kosten
Oct 17, 2008·Journal of Medicinal Chemistry·Jennifer B TreweekKim D Janda
Apr 25, 2007·The Journal of Pharmacology and Experimental Therapeutics·Eric C PetersonS Michael Owens
Jul 14, 2009·Molecular Interventions·Eric C Peterson, S Michael Owens
Nov 18, 2009·Pharmacology & Therapeutics·Bianca Jupp, Andrew J Lawrence
Dec 27, 2015·Heart, Lung & Circulation·Elizabeth D ParatzAndrew I MacIsaac
Sep 18, 2009·Protein Science : a Publication of the Protein Society·Reha CelikelKottayil I Varughese
Nov 11, 2008·Annals of the New York Academy of Sciences·Frank M OrsonThomas R Kosten
Oct 9, 2012·British Journal of Clinical Pharmacology·Ariadna Forray, Mehmet Sofuoglu
Mar 21, 2013·British Journal of Clinical Pharmacology·Thomas KostenBerma Kinsey
Jun 23, 2010·British Journal of Clinical Pharmacology·Laurent KarilaSteven L Batki
Dec 16, 2010·Brain Research·Oksana PolesskayaStephen Dewhurst
Oct 2, 2012·Drug and Alcohol Dependence·Xiaoyun Y ShenFrank M Orson
Jul 22, 2016·Human Vaccines & Immunotherapeutics·Marco Pravetoni
Feb 1, 2019·The American Journal on Addictions·Reetakshi AroraThomas R Kosten
Jul 14, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ahmed ElkashefFrank Vocci
Mar 1, 2008·Expert Review of Clinical Pharmacology·David A Gorelick
May 21, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Sarah J WhiteS Michael Owens
Feb 29, 2008·The Journal of Pharmacology and Experimental Therapeutics·Samuel A RoikoPaul R Pentel
Dec 2, 2011·Clinical Pharmacology and Therapeutics·X Y ShenT R Kosten
Sep 17, 2013·Clinical Cardiology·Sekon WonNisha I Parikh
Aug 31, 2021·RSC Chemical Biology·Jinny Claire Lee, Kim D Janda

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.